Our global product development and supply organization is the backbone of the delivery of medicine for patients around the world, which translates science into innovative treatments.
BMS has become a leading life science presence in Massachusetts, and our 89-acre Devens campus underpins and advances manufacturing operations for BMS biologics and cell therapies.
Located northwest of Boston, our campus supports process development, clinical manufacturing and commercial manufacturing for biologics and cell therapy medicines.
This work is brought to live by 1,700 employees at the campus, all dedicated to our vision of transforming patients lives through science.
Biologics require highly specialized facilities and top of the line infrastructure.
At Devens we support the total BMS pipeline for biologics.
Process development takes place in our labs, clinical manufacturing in our state of the art single-use manufacturing facility and the manufacture of multiple licensed products happens in two commercial facilities.
Our direct connection to the entire biologics portfolio makes for a very exciting time to be in Devens.
Our cell therapy facility, where we manufacture a cutting edge, personalized treatment that uses a patient´s own cells to treat their specific cancer.
CAR T cell therapy gives patients with certain difficult to treat like cancers a chance of remission.
In this manufacturing process, a patient´s blood is collected at their treatment center in a process called apheresis. Then the blood product is shipped to our facility, where we re-engineer the cells to fight the patient´s specific cancer. Once the manufacturing and testing process is complete, the cells are sent back to the treatment center and reinforce back into the patient, where they can now recognize and attack the cancer cells.
Our cell therapy facility allows us to integrate the latest manufacturing equipment and digital technology to help deliver personalized cell therapies to as many patients as we can, as fast as we can.
We are proud of the network of people we have built in Devens, and the growth that has yet to come.
We have incredibly passionate and talented people, driven by one common mission in mind, to develop and deliver innovative medicines that help patients prevail over serious diseases.
The Devens campus is a place to grow your career with opportunities across biologics and cell therapy.
We continually invest in our people to enable the next generation of pharmaceutical innovation for our patients.
I´m very proud of all we do for people every single day, for our patients, for our employees, and for our communities.
At the Bristol Myers Squibb Devens, Massachusetts, manufacturing site, innovation is not a future aspiration, it is how the facility operates every day. Purpose-built to manufacture some of the industry’s most complex biologics and cell therapies, Devens represents a new model for how advanced medicines can be developed, scaled and delivered with speed, precision, and sustainability.
Manufacturing biologics and cell therapies presents a distinct set of challenges. Products derived from living systems operate with inherent variability, require tight process controls and must meet exact quality requirements. The Devens site integrates biopharma science with digital, data and AI-enabled solutions to better manage complexity across the full production lifecycle.
Today, more than 30 advanced digital and AI use cases are deployed end-to-end at Devens, embedded directly into operations rather than layered on top. These tools support predictive process monitoring, advanced analytics, real-time decision support and smarter orchestration of manufacturing and quality activities. Together, they enable teams to anticipate variability, respond faster and continuously improve performance across both biologics and cell therapy production.
The impact is significant and measurable. Devens has reduced new product introduction timelines by 42%, increased production volumes by more than 40% and lowered emissions by over 40%, demonstrating that digital transformation can simultaneously drive speed, scale and sustainability efforts. These gains reflect not only technology adoption, but a deliberate operating model that empowers multidisciplinary teams to act on insights with confidence.
The site’s physical and digital infrastructure was designed with adaptability and growth in mind. Advanced automation, digitally connected systems and modular manufacturing suites allow Devens to evolve alongside scientific advances and changing patient needs. Just as important is the culture behind the technology: engineers, scientists and digital experts working together to continuously improve performance and execution at scale.
In 2026, this approach earned global recognition when the Devens site was named a Global Lighthouse by the World Economic Forum, the only manufacturing site in North America to receive the designation that year. The recognition honors facilities that have successfully scaled Fourth Industrial Revolution technologies to deliver real-world impact. At Devens, the designation serves less as a destination and more as validation of a model already in motion.
As Bristol Myers Squibb continues to advance next-generation biologics and cell therapies, Devens stands as a blueprint for the future of biopharmaceutical manufacturing, one where digital innovation, resilient supply, sustainability and patient impact move forward together.
